comprehensive -WSS

comprehensive

author：fashion 2025-08-24 23:09:55 - browse：49

New Sanofi Genzyme president Bill Sibold is the first person without any ties to Henri Termeer (inset) to lead the company. Jonathan Wiggs/Globe staff

CAMBRIDGE, Mass. — When drug giant Sanofi restructured its global business two years ago, its Genzyme division got a new name, Sanofi Genzyme, explicitly tying it to the French parent company. It also got new responsibilities and a larger “specialty care” portfolio covering everything from enzyme replacement to cancer and multiple sclerosis drugs.

Last week, Sanofi Genzyme — still the largest Massachusetts biotech, with about 5,000 workers — also got a new president, Bill Sibold. He’s the first one without any ties to the old Genzyme, an independent company that pioneered the rare-disease business model and catalyzed the local life sciences boom before accepting Sanofi’s $20.1 billion takeover offer in 2011.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

WSS

Why age limits for politicians are a terrible idea

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Senate panel eyes new effort on drug shortages

Bill would stop addiction treatment from triggering child abuse inquiry

Dramatically reducing cancer deaths requires the PASTEUR Act

leisure time

comprehensive

explore

23andMe had bad news about my health. I wish a person had delivered it

Verily hires former Apple Health leader as chief scientific officer

Wildfire smoke exposes gaps in outdoor worker protections

Attacks on the drug industry will lead to fewer breakthroughs

Medical records are filled with copy

A Q&A with the global head of Boehringer Ingelheim's innovation unit

In age of alternative facts, a scholarly course on calling out crap

Influencer to be charged after chaos erupts in New York City's Union Square

Moonlake's readout produced a cash windfall. Risks remain

Physician executives need more than on

focus

Attacks on the drug industry will lead to fewer breakthroughs

ER docs worry over extreme heat as a 'mass casualty event'

VC firm General Catalyst wants to buy a health system

Colorectal cancer study finds potential in overlooked immune cell

3 questions for the future of Biden's cancer moonshot

When women are denied an abortion, their children fare worse than peers

hotspot

focus

hotspot

hotspot